贝达药业：关于盐酸恩沙替尼胶囊术后辅助治疗适应症药品注册申请获得受理的公告

Core Viewpoint - Betta Pharmaceuticals has received acceptance from the National Medical Products Administration (NMPA) for its application of crizotinib capsules (brand name: Baimena®) for postoperative adjuvant therapy in ALK-positive non-small cell lung cancer (NSCLC) patients [2] Group 1 - The NMPA issued an acceptance notice for the application with reference numbers CXHS2500142 and CXHS2500143 [2] - The indication for the drug is specifically for patients with stage IB to IIIB ALK-positive NSCLC who have previously undergone surgical resection [2] - The decision for patients to receive adjuvant chemotherapy is at the discretion of their physician [2]